SERPENSE TREATMENT OF BENIGN PROSTATIC HY PERPLASIA

320 mg of serpense was given daily to 24 patients with benign prostati c hyperplasia (BPH) for 2 months. Control check-ups were performed eac h 30 days. The effect was judged by the patient's condition (I-PSS), q uality of life, residuar urine, the grand size, urodynamic picture and level of prostatic specific antigen (PSA). The response of BPH to ser pense was noticeable, especially at the first stage of the disease (66 .7%). Reduced serum PSA in serpense-treated patients may be explained by peripheral selective inhibition of 5 alpha-reductase or, rather, by antiinflammatory action of the drug. Antidropsical and antiinflammato ry actions of serpense suggest its possible efficacy in chronic prosta titis.